key: cord-0858319-tu9wj452 authors: Vahidy, F. S.; Pischel, L.; Tano, M. E.; Pan, A. P.; Boom, M. L.; Sostman, H. D.; Nasir, K.; Omer, S. B. title: Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States date: 2021-04-23 journal: nan DOI: 10.1101/2021.04.21.21255873 sha: acd5605dffae75c41831df20001481da0d1b6eab doc_id: 858319 cord_uid: tu9wj452 Background: Covid-19 has caused significant global mortality. Multiple vaccines have demonstrated efficacy in clinical trials though real-world effectiveness of vaccines against Covid-19 mortality in clinically and demographically diverse populations has not yet been reported. Methods: We used a retrospective cohort assembled from a cross-institution comprehensive data repository. Established patients of the health care system were categorized as not immunized, partially immunized, or fully immunized against SARS-CoV-2 with an mRNA vaccine through April 4, 2021. Outcomes were Covid-19 related hospitalization and death. Results: Of the 91,134 established patients, 70.2% were not immunized, 4.5% were partially immunized and 25.4% were fully immunized. Among the fully immunized 0.7% had a Covid-19 hospitalization, whereas 3.4% among the partially immunized and 2.7% non-immunized individuals were hospitalized with Covid-19. Of the 225 deaths among Covid-19 hospitalizations, 219 (97.3%) were in the not immunized, 5 (2.2%) in the partially immunized, and 1 (0.0041%) in the fully immunized group. mRNA vaccines were 96% (95%CI: 95 - 99) effective at preventing Covid-19 related hospitalization and 98.7% (95%CI: 91.0 - 99.8) effective at preventing Covid-19 related death when participants were fully vaccinated. Partial vaccination was 77% (95%CI: 71 - 82) effective at preventing hospitalization and 64.2% (95%CI: 13.0 - 85.2) effective at preventing death. Vaccine effectiveness at preventing hospitalization was conserved across subgroups of age, race, ethnicity, Area Deprivation Index, and Charlson Comorbidity Index. Conclusions: In a large, diverse cohort in the United States, full immunization with mRNA vaccines was highly effective in the real-world scenario at preventing Covid-19 related hospitalization and death. The Covid-19 pandemic has caused great suffering and mortality across the globe since the pathogen Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged late in 2019. The United States (US) has been disproportionately affected by SARS-CoV-2 in terms of mortality and according to preliminary mortality data, Covid-19 was the third leading cause of death in the US in 2020 with 91.5 deaths per 100,000 of the population or 11.3% of all deaths. 1 Due to the Covid-19 pandemic, life expectancy in the US dropped by one full year in 2020 comparing to 2019. 2 Vaccines against SARS-CoV-2 remain the most effective means to stymie the morbidity and mortality attributable to this virus and curb its global spread. Three vaccines currently have currently received emergency use authorization in the US-all with high vaccine efficacy in clinical trials. [3] [4] [5] The real-world effectiveness of Covid-19 outside of clinical trials is needed to inform clinical and policy decisions. The reporting of real-world effectiveness, particularly against severe forms of Covid-19 requiring hospitalization or leading to mortality, may also help alleviate some hesitancy around vaccination. The United States' experience with Covid-19 vaccines represents an important opportunity for the study of vaccine effectiveness due to the high burden of Covid-19, the high prevalence of underlying comorbidities, and the diverse population. The US, compared to many other countries, has administered earlier mass Covid-19 vaccination programs which allows for longer follow-up time. Prior real-world cohort studies have not addressed the impact of Covid-19 vaccination on mortality after full vaccination. Estimating the vaccines' effectiveness at reducing Covid-19 mortality remains an important question as the clinical trials that allowed for their approval did not have large enough sample sizes to precisely estimate mortality benefit from vaccination. To address this question, we assembled a large diverse retrospective cohort from a single health care system in the US. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Furthermore, CURATOR houses longitudinal data on all prior and subsequent hospital and outpatient encounters for the included testing and vaccination cohorts. In this cohort, we identified established HM patients (described subsequently) for whom comprehensive follow-up data were available. Houston Methodist rolled out Covid-19 vaccination across all of its hospitals simultaneously starting December 15, 2020. We identified individuals in CURATOR who had at All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. Persons were excluded if they received vaccine other than the two primary mRNA Covid-19 vaccines being used by the health system: 25,828 BNT162b2 or mRNA-1273. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255873 doi: medRxiv preprint Demographics (age, sex, race, ethnicity, area deprivation index [ADI], zip code-based income), risk factors (tobacco/alcohol use and obesity) and comorbidities included in the Charlson comorbidity index (CCI) were obtained from CURATOR for the included study participants. No study participants had missing data on vaccination and outcomes. Missing data for covariates are reported and complete case analyses were utilized for adjusted estimates. Descriptive summary statistics are provided as frequencies, proportions with 95% confidence intervals (CI), means (standard deviations [SD]) or medians with interquartile range (IQR). We fit multivariable cox-proportional hazard models adjusted for age, sex, race, ethnicity, ADI and CCI and report hazard ratios (HR) with 95% CI for hospitalization risk associated with various immunization states. Vaccine effectiveness (VE) was calculated as 1 -HR. VE across various age, race, ethnicity, ADI and CCI sub-groups was also evaluated. Evolution of odds ratios (OR) over time was determined to estimate the risk of hospitalization associated with cohort transition across states of partial and full immunization during the study period. Owing to the small number of Covid-19 mortality events, OR and VE (1 -OR) were reported among the fully and partially immunized cohorts (compared to unimmunized) without any adjusted analyses. All analyses were performed in a statistical computing environment supported by R (version 3.6.1) and Python. Python packages lifeline version 0.25.10 were used for time-toevent analyses. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. higher levels of cardiovascular, cerebrovascular, metabolic, and renal comorbidity burden as demonstrated by an overall higher CCI median (IQR); 6 (3 -9) among the fully immunized compared to 4 (2 -8) among partially immunized and 3 (1 -7) among the unimmunized. Overall, 28,988 first doses of the two mRNA vaccines were administered in the included cohort, some of which were counted in the unimmunized group, as the 14-day partial immunization threshold had not been achieved. Of these, 26,312 (90.8%) were for the BNT162b2 vaccine whereas 2,676 (9.2%) represent the mRNA-1273.351 vaccine. During the study period, a total of 2,017 (2.2%) patients were hospitalized for Covid-19. Among the fully immunized 0.7% (95% CI: 0.6 -0.9) had a Covid-19 hospitalization; whereas 3.4%( 95% CI: 2.9-4.1%) among the partially immunized and 2.7% (95% CI: 2.5 -2.8) nonimmunized individuals were hospitalized with Covid-19 (Figure 1) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255873 doi: medRxiv preprint group. The rolling time-dependent, cumulative vaccine effectiveness (VE: 1 -OR) and 95% CI for the partially and fully immunized groups vs. the not immunized demonstrates consistent vaccine effectiveness over time (Supplemental Figure 1) . In the sub-group analysis for the fully immunized cohort, VE against Coivd-19 hospitalization was ≥ 93% for all subgroups and was conserved across age, race, ethnicity, ADI, and CCI subgroups. (Figure 3) . Overall, 225 deaths among Covid-19 hospitalizations were observed in the cohort, 219 Table 2) . This is the first large study to examine the real-world effectiveness of Covid-19 vaccinations at preventing hospitalizations and death in the US. Moreover, this is the first study anywhere to evaluate the impact of full immunization on Covid-19 mortality. The two mRNA Covid-19 vaccines were highly protective against hospitalization and death especially in those who were fully immunized. In our analyses, mRNA vaccines were 96% (95%CI: 95 -99) effective at preventing Covid-19 related hospitalization and 98.7% (95%CI: 91.0-99.8) effective at preventing Covid-19 related death when participants were fully immunized. Partial immunization, defined as hospitalization more than 14 days after dose 1 of an mRNA vaccine through 7 days after dose All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 9 . This study specifically looked at preventing hospitalization specifically in patients over 80 years of age, as opposed to the population at large or the VE at reducing mortality. Separately in Israel, Dagan and colleagues reported a 74% effectiveness at preventing hospitalization and a 72% effectiveness at preventing death with partial vaccination. 10 Full vaccination was 87% effective at preventing hospitalization and 92% effective at preventing severe disease. Our study adds value by evaluating VE for preventing death for both partial and full vaccination. There has been considerable public discussion of increasing vaccine access by administering a single dose of a two-dose vaccine or at least delaying the second dose. Prior studies of VE in the US looked at the impact of partial immunization and full immunization on Covid-19 in certain special populations. Our findings suggest that partial immunization (i.e., receipt of one dose of an mRNA vaccine) is associated with reduced protection against severe disease leading to hospitalization and poor outcomes such as in-hospital mortality. While we document lower effectiveness against mortality, the estimates are imprecise due to the small number of outcome events. However, the point estimate of effectiveness against mortality as well as VE against hospitalization suggest that policy-makers should account for the lower level All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Limitations of this study include its observational design, as there may have been some differences in testing behavior between those who were unvaccinated, partially vaccinated and fully vaccinated that are unaccounted for in this analysis. For example, there may have been differences in health-seeking behavior between these groups or different thresholds to test for SARS-CoV-2 amongst clinicians. However, it is unlikely there were large differences in hospitalization rates based on behavior alone. Across the pandemic timeline, the criteria for hospitalization have been consistently based on risk stratification by evaluation of the severity of symptoms, comorbidities, diagnostic findings and pulse oximetry. Second, as this is an observational study, there may be some residual unmeasured confounding, however, this is unlikely to alter the overall interpretation. It is also possible that certain individuals in the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255873 doi: medRxiv preprint established cohort may have been tested and/or hospitalized elsewhere in the region. However, our healthcare system has a relatively high rate of patient retention. For example, in the overall tested cohort in CURATOR, > 95% have had at least one prior healthcare system encounter. Overall the vaccine effectiveness seen in this study was similar to the vaccine efficacy of clinical trials, which is reassuring. Finally, this study only examined two of the three vaccines currently approved for use in the US due to the timing of the study. It will be important going forward to study the real-world effectiveness of the different Covid-19 vaccines approved in the US and across the globe. Conclusion: To date, this is the largest Covid-19 VE cohort study in the US. In this diverse and well-characterized cohort, we show Covid-19 vaccines have a large impact in reducing Covid-19 hospitalization and mortality. Vaccines remain the central tool for disease control strategies and so ensuring broad and equitable access to vaccines remains imperative for pandemic control moving forward. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255873 doi: medRxiv preprint Disaggregation of hospitalization cases for the fully, partial, and unimmunized cohorts is presented in the left part of the figure and VE (95% CI) for the fully immunized cohort in the right one. * Asian and Native American participants have been included in the 'Others' category 20 ht All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255873 doi: medRxiv preprint Provisional Mortality Data -United States Provisional Life Expectancy Estimates for Efficacy and Safety of the mRNA-1273 SARS CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Jannsen Ad26.COV2.S Vaccine for the Prevention of COVID-19 Vaccines and Related Biological Products Advisory Committee Learning Health Care System: Rationale and Design of the Houston Methodist Surveillance and Outcomes Registry (CURATOR) Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalizations in elderly and frail adults: a single centre test negative case-control study Centers for Disease Control and Prevention. Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity. 2021 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder